SYL040012, Treatment for Open Angle Glaucoma

NCT02250612 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

184

Enrollment

INDUSTRY

Sponsor class

Conditions

Open Angle Glaucoma
Ocular Hypertension

Interventions

DRUG: 1 drop of 0.375% SYL040012 (bamosiran)
DRUG: 1 drop of 0.750% SYL040012 (bamosiran)
DRUG: 1 drop of 1.125% SYL040012 (bamosiran)
DRUG: 1 drop of 1.5% SYL040012 (bamosiran)
DRUG: 1 drop of 0.5 % timolol maleate

Sponsor

Sylentis, S.A.